<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409380</url>
  </required_header>
  <id_info>
    <org_study_id>FWA 00006218</org_study_id>
    <nct_id>NCT03409380</nct_id>
  </id_info>
  <brief_title>Supplementation Trial on Arginine With Metabolic Profiling</brief_title>
  <acronym>STAMP</acronym>
  <official_title>Supplementation Trial on Arginine With Metabolic Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jennifer C. Rood</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robbie A. Beyl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corby K. Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frank L. Greenway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess effects of an acute dose of the amino acid arginine on metabolism in&#xD;
      healthy young men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double - blind randomized, crossover design trial examining arginine vs. placebo beverage&#xD;
      treatments will be performed. The primary objective is to determine the effects of arginine&#xD;
      assessed by standard laboratory assays and metabolomics. To accomplish the objective&#xD;
      standardized meals will be provided for 2 days preceding treatment for dietary consistency.&#xD;
      Participants will arrive at the center following a 10-12 hr fast. Blood samples will be&#xD;
      collected at baseline (fasting), 1.5 hrs, 3.0 hrs, 6.0 hrs, and 24 hrs post treatment. Plasma&#xD;
      prolactin, growth hormone, amino acids, glucose, insulin, triacylglycerols, thyroid hormones&#xD;
      (TSH, T3, and T4), sex hormone binding globulin (SHBH), testosterone, cortisol, DHEA, and&#xD;
      citrulline will be measured. Metabolomics will be measured at 3 time points for each&#xD;
      treatment. Peripheral arterial tonometry (PAT) will also be performed at ~2 hrs following&#xD;
      treatment to examine endothelial function in response to nitrous oxide release. In addition,&#xD;
      psychological status including fatigue will be assessed using a standardized mood&#xD;
      questionnaire (POMS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double - blind randomized, crossover design trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth Hormone</measure>
    <time_frame>baseline (fasting), 1.5, 3.0, 6.0, and 24.0 hrs</time_frame>
    <description>Change in GH</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Protein</condition>
  <condition>Amino Acid</condition>
  <condition>Arginine</condition>
  <arm_group>
    <arm_group_label>Arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arginine drink provided 1 time. There is about 10 g of arginine in the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drink provided 1 time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arginine Drink</intervention_name>
    <description>10 g of arginine in a formulated drink</description>
    <arm_group_label>Arginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plain Drink</intervention_name>
    <description>formulated drink</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18.5 - 25 kg/m2.&#xD;
&#xD;
          -  Must be physically active (exercise at least 2 days/week).&#xD;
&#xD;
          -  Willing to refrain from alcohol and supplements for the duration of the study.&#xD;
&#xD;
          -  Willing to refrain from supplement ingestion, nuts, watermelon, and cracklins&#xD;
             (fatback) for the 2 weeks prior to the initial treatment diet through the duration of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV or AIDS&#xD;
&#xD;
          -  Uncontrolled CVD/arrhythmia&#xD;
&#xD;
          -  Type I or type II diabetes&#xD;
&#xD;
          -  Pregnancy (or breastfeeding)&#xD;
&#xD;
          -  Diagnosed eating disorder&#xD;
&#xD;
          -  Non-normal sleeping patterns&#xD;
&#xD;
          -  Chronic neurological condition&#xD;
&#xD;
          -  Altered metabolism including growth hormone disorders&#xD;
&#xD;
          -  Use of nicotine or tobacco products&#xD;
&#xD;
          -  Heavy caffeine use (â‰¥ 350 mg caffeine/d)&#xD;
&#xD;
          -  Whole blood donation within previous eight weeks&#xD;
&#xD;
          -  Protein supplementation&#xD;
&#xD;
          -  Protein wasting disease.&#xD;
&#xD;
          -  Exclusionary medications include diuretics, beta-blockers, weight loss medications or&#xD;
             diet pills, anti-inflammatory drugs (corticosteroid/ anabolic steroid/NSAID),&#xD;
             antipsychotic medication or other medication that may affect fluid balance,&#xD;
             metabolism, or body weight.&#xD;
&#xD;
          -  Prisoners and adults who are unable to consent will be excluded from the study.&#xD;
&#xD;
          -  Lastly any other medical, psychiatric, or behavioral factors in the judgement of the&#xD;
             Principle Investigator that may interfere with study participation or the ability to&#xD;
             follow the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>John Apolzan</investigator_full_name>
    <investigator_title>Asst Professor</investigator_title>
  </responsible_party>
  <keyword>growth hormone</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

